Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.
Compass Pathways, a UK-based depression medicine developer backed by pharmaceutical group Otsuka Pharmaceuticals’ McQuade Center for Strategic Research and Development, went public in an IPO worth more than $127m on Friday.
The company issued 7.5 million American Depositary Shares (ADSs) priced at $17, having initially planned to sell 6.7 million shares within a range of $14 to $16.
The company has listed on the Nasdaq Global Select Market and currently has a market cap of more than $986m. Its shares…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
